Hip surgery: minimal-opiate multimodal regimen improves pain control

  • Fleischman AN & al.
  • J Am Coll Surg
  • 5 Jun 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Patients who underwent surgery for total hip replacement (THR) whose postoperative pain was managed with a multimodal analgesic regimen that included fixed-schedule doses of acetaminophen, meloxicam, and gabapentin and only a 2-day supply of prescription opioids reported superior pain relief than those managed with the traditional approach of as-needed opiates.

Why this matters

  • Previously published research suggests that the demand for primary THR in the United States is estimated to grow by 174% by 2030.

Study design

  • Parallel-group, cluster-randomized OPIOID study of 235 patients who, after undergoing THR, were randomly assigned to:
    • multimodal analgesic regimen (fixed-schedule doses of acetaminophen, meloxicam, and gabapentin)+2-day opiate supply;
    • multimodal analgesic regimen+2-week opiate supply; or
    • acetaminophen+2-week opiate supply (control group).
  • Funding: None disclosed.

Key results

  • At 30 days, visual analog scale (VAS) pain scores were significantly lower with multimodal analgesia vs control group:
    • 2-day opiate group: coefficient, −0.81 (P=.003).
    • 2-week opiate group: coefficient, −0.61 (P=.021).
  • VAS pain scores were not significantly different between the 2 multimodal analgesic groups.
  • Multimodal analgesic with 2-day opiate supply had significantly lower:
    • daily morphine equivalents vs 2-week supply (coefficient, −0.46; P=.002) and control group (coefficient, −0.77; P<.001 and>
    • composite opioid-related symptom distress scale score vs control group (P=.005).

Limitations

  • Patient-reported opioid consumption.

Coauthored with Antara Ghosh, PhD